Tvardi Therapeutics is a private, clinical-stage biotechnology company developing a new class of breakthrough medicines for diverse cancers, fibrotic, and chronic inflammatory diseases. Tvardi is focused on the development of orally delivered, small-molecule inhibitors of STAT3, a key signaling protein positioned at the intersection of these disease pathways.